Shanghai, China-based Wuxi Biologics inked a deal with Germany’s Bayer to take over the operations of Bayer’s drug manufacturing factory in Leverkusen, Germany. It is also buying the equipment in […]
When Amgen shelled out $13.4 billion late last year to pick up Celgene’s blockbuster immunology med Otezla, it made a calculated guess the drug had some untapped fuel in its […]
After taking the reins at Gilead early last year, CEO Daniel O’Day’s been heading up the company long enough to understand what investors really want: more transparency and M&A clues. […]
Around this time last year, market watchers were digesting the surprise news that Bristol-Myers Squibb and Celgene had struck a megamerger deal. While 2020 hasn’t started in similar style, a […]
Eli Lilly has announced plans to buy Dermira for around $1.1 billion, expanding its immunology pipeline in the process. As part of the agreement Lilly will add lebrikizumab, Dermira’s moderate-to-severe […]
